Skip to Main Content
Table 3

Mean blood glucose concentration and daily insulin doses during subcutaneous insulin treatment after resolution of DKA

Mean daily blood glucose (mg/dl)
PMean daily insulin dose (units/day)
P
NPH/regularGlargine/glulisineNPH/regularGlargine/glulisine
Day 1* 188 ± 61 213 ± 76 0.234 50 ± 28 58 ± 33 0.304 
Day 2 206 ± 71 220 ± 61 0.370 70 ± 37 73 ± 47 0.877 
Day 3 207 ± 86 180 ± 80 0.417 77 ± 45 62 ± 49 0.364 
Day 4 211 ± 63 158 ± 44 0.068 70 ± 47 67 ± 50 0.999 
Day 5 190 ± 45 124 ± 41 0.068 50 ± 30 47 ± 41 0.302 
Mean daily blood glucose (mg/dl)
PMean daily insulin dose (units/day)
P
NPH/regularGlargine/glulisineNPH/regularGlargine/glulisine
Day 1* 188 ± 61 213 ± 76 0.234 50 ± 28 58 ± 33 0.304 
Day 2 206 ± 71 220 ± 61 0.370 70 ± 37 73 ± 47 0.877 
Day 3 207 ± 86 180 ± 80 0.417 77 ± 45 62 ± 49 0.364 
Day 4 211 ± 63 158 ± 44 0.068 70 ± 47 67 ± 50 0.999 
Day 5 190 ± 45 124 ± 41 0.068 50 ± 30 47 ± 41 0.302 

Data are means ± SD.

*Day 1 = depending on the time of resolution of ketoacidosis and transition to subcutaneous insulin, a patient could have received one or two doses of NPH/regular insulin or one dose of glargine and one to three doses of glulisine insulin per day.

Close Modal

or Create an Account

Close Modal
Close Modal